摘要
本文总结1例嵌合抗原受体T(chimeric antigen receptor T,CAR-T)细胞治疗失败的难治性弥漫大B细胞淋巴瘤患者,在合并新型冠状病毒(coronavirus disease 2019,COVID-19)情况下接受格菲妥单抗治疗后获得完全缓解,且未见COVID-19感染加重等其他严重不良反应的治疗经验,同时回顾文献中格菲妥单抗治疗难治性弥漫大B细胞淋巴瘤的疗效,以及双特异性抗体在合并COVID-19的淋巴瘤患者中的安全性。
The data of a patient with refractory diffuse large B-cell lymphoma,who was failed to chimeric antigen receptor T(CAR-T)cell therapy,are analyzed in this report.The patient achieved complete remission after receiving glofitamab with combination of coronavirus disease 2019(COVID-19),and no other serious adverse events such as aggravation of COVID-19 were observed.Meanwhile,the efficacy of Glofitamab in the treatment of refractory diffuse large B-cell lymphoma is reviewed,and the safety of bispecific antibodies in patients with lymphoma complicated with COVID-19 is evaluated.
作者
毕江涵
张炎
王为
BI Jianghan;ZHANG Yan;WANG Wei(Department of Internal Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College;Department of Hematopathology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《中国癌症防治杂志》
CAS
2024年第5期566-570,共5页
CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
基金
北京协和医学院2023年中央高校教育教学改革专项资金支持项目(2023zlgl 050)。
